Loading...
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
Immune checkpoint inhibitors (ICI) have revolutionised cancer therapy. However, they have been effective in only a small subset of patients and a principal mechanism underlying immune-refractoriness is a ‘cold’ tumour microenvironment, that is, lack of a T-cell-rich, spontaneously inflamed phenotype...
Na minha lista:
| Udgivet i: | J Clin Med |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7602874/ https://ncbi.nlm.nih.gov/pubmed/33081170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9103323 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|